Semafore’s PI3 Kinase Inhibitor SF1126 Is Active Against Tumor And Tumor Cells And Synergizes With Standard Chemotherapy Agents

Semafore Pharmaceuticals Inc. announced on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain standard chemotherapy agents in vitro and in vivo (poster C207). In vitro data showed significant (p [click link for full article]

More: continued here

Filed under: Cancer on October 28th, 2007